December 3, 2020
Olaparib Granted Positive EU Opinion for BRCA1/2+ Advanced Prostate CancerBookmarkGeorge Lundberg, MD
A news story published by OncLive reports that the European Union’s Committee for Medicinal Products for Human Use recently approved the drug olaparib for treating patients with a subset of advanced castrate-resistant prostate cancers that have BRCA1/2 mutations.
September 18, 2018
Biomarkers, PARP Inhibitors Vital for Personalized Treatment in Breast Cancer SubtypesBookmarkEmma Shtivelman, PhD
Excerpt from OncLive:
“Developing predictive biomarkers will be key to treating patients with triple-negative breast cancer (TNBC), especially when choosing a targeted therapy, said Banu K. Arun, MD.
“In a presentation during the 2018 OncLive® State of the Science Summit™ on Breast Cancer, Arun said there is evidence that PARP inhibitors as well as immunotherapy in combination with various agents may be effective in women with TNBC and BRCA1-related breast cancers, but the science isn’t there yet.”
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.